^
Association details:
| Biomarker: | PD-L1 expression + MSI-L/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report
Published date:
08/03/2020
Excerpt:
A 58-year-old man was diagnosed with transverse colon cancer during chemotherapy with pembrolizumab for NSCLC....The histopathological diagnosis was undifferentiated carcinoma with rhabdoid features and lymph node metastasis. Immunohistochemically, programmed death ligand 1 (PD-L1) showed positivity. The microsatellite instability (MSI) status was low. He continued to receive pembrolizumab for NSCLC, and there have been no signs of colon cancer recurrence and progression of NSCLC for 15 months....The development of the tumor with the expression of PD-L1 during pembrolizumab might have been associated with the low MS.
DOI:
10.1186/s40792-020-00963-1
